Related Experiment Video
Updated: Oct 29, 2025
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
The potential of CAR T cell therapy for prostate cancer
Philipp Wolf1,2, Jamal Alzubi3,4, Christian Gratzke5,6
1Faculty of Medicine, University of Freiburg, Freiburg, Germany. philipp.wolf@uniklinik-freiburg.de.
Abstract:
Chimeric antigen receptor (CAR) T cell immunotherapy involves the genetic modification of the patient's own T cells so that they specifically recognize and destroy tumour cells. Considerable clinical success has been achieved using this technique in patients with lymphoid malignancies, but clinical studies that investigated treating solid tumours using this emerging technology have been disappointing. A number of developments might be able to increase the efficacy of CAR T cell therapy for treatment of prostate cancer, including improved trafficking to the tumour, techniques to overcome the immunosuppressive tumour microenvironment, as well as methods to enhance CAR T cell persistence, specificity and safety. Furthermore, CAR T cell therapy has the potential to be combined with other treatment modalities, such as androgen deprivation therapy, radiotherapy or chemotherapy, and could be applied as focal CAR T cell therapy for prostate cancer.
Insights
Chimeric antigen receptor (CAR) T cell immunotherapy shows promise for lymphoid cancers but struggles with solid tumors like prostate cancer. Future advancements aim to improve CAR T cell therapy efficacy for solid tumors through enhanced trafficking, overcoming tumor defenses, and combination treatments.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Therapy
Background:
- Chimeric antigen receptor (CAR) T cell therapy genetically modifies a patient's T cells to target cancer cells.
- CAR T cell therapy has shown significant success in lymphoid malignancies.
- Treating solid tumors, such as prostate cancer, with CAR T cells has yielded disappointing results.
Purpose of the Study:
- To explore strategies for enhancing CAR T cell therapy efficacy in prostate cancer.
- To address challenges hindering CAR T cell treatment of solid tumors.
Main Methods:
- Investigating methods to improve CAR T cell trafficking to the tumor site.
- Exploring techniques to overcome the immunosuppressive tumor microenvironment.
- Examining strategies to enhance CAR T cell persistence, specificity, and safety.
Main Results:
- Current clinical studies for solid tumors have been disappointing.
- Several potential developments could improve CAR T cell therapy for prostate cancer.
Conclusions:
- CAR T cell therapy holds potential for prostate cancer treatment with further advancements.
- Combination therapies (androgen deprivation, radiotherapy, chemotherapy) and focal CAR T cell therapy are potential applications.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...